ArticleWorld journal of surgical oncology2026
Analysis of the proliferative role and prognostic value of GPR173 in gastric cancer.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- New insights into SREB orphan receptor roles in the ovary, using comparative transcriptomics across 3 fishes.Endocrinology · 2026Article
- Elucidating the dual regulation of apoptosis and migration by Ajugasterone C in AGS cells via the PI3K/AKT pathway.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is a leading cause of cancer-related death with a poor prognosis, highlighting an urgent need for novel therapeutic targets and biomarkers. The function of G protein-coupled receptor 173 (GPR173), an orphan receptor, remains unknown in GC. This study aimed to comprehensively characterize the clinical significance and biological function of GPR173 in GC.
methodsWe analyzed GPR173 expression and its prognostic value using data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and an in-house clinical cohort (consisting of 136 gastric cancer patients) via immunohistochemistry. The biological functions of GPR173 were investigated through in vitro gain- and loss-of-function assays (CCK-8, colony formation, EdU) and an in vivo xenograft model. The underlying molecular mechanism was explored using bioinformatics, Western blotting, and immunofluorescence.
resultsGPR173 was upregulated in GC tissues across TCGA, GEO, and internal cohorts (all P < 0.01), correlating with advanced T (P = 0.016) and N stages (P = 0.002). Multivariate analysis identified high GPR173 as an independent prognostic factor in both the TCGA (HR = 1.33, P = 0.0076) and our clinical cohort (HR = 2.35, P = 0.014). Functionally, GPR173 promoted cell proliferation in vitro and tumor growth in vivo (P < 0.001). Mechanistically, GPR173 activated PI3K/AKT signaling, and the AKT inhibitor MK-2206 reversed these oncogenic effects.
conclusionOur findings establish GPR173 as a novel oncogene in gastric cancer that promotes tumor progression through activation of the PI3K/AKT pathway. GPR173 serves as a robust prognostic biomarker for poor patient survival, representing a potential new therapeutic target for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.